Bnp Paribas Asset Management Holding S.A. Arcus Biosciences, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 1,395,726 shares of RCUS stock, worth $13.5 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,395,726
Previous 1,628,019
14.27%
Holding current value
$13.5 Million
Previous $12.8 Million
11.09%
% of portfolio
0.03%
Previous 0.03%
Shares
17 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
65.5MCall Options Held
3.1MPut Options Held
148K-
Black Rock Inc. New York, NY9.76MShares$94.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$63.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$57.7 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$38.7 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$35.7 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $698M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...